52,621 Shares in CVS Health Corporation $CVS Purchased by Western Financial Corp CA

Key Points

• Western Financial Corp CA acquired 52,621 CVS shares worth approximately $4.5 million in the third quarter, making CVS its 17th-largest holding and representing 1.5% of its portfolio. Institutional investors collectively own 80.66% of CVS.
• CVS shares rose 3.3% to $90.42, while the company reported quarterly earnings of $2.58 per share—well above the $1.87 consensus estimate—and revenue of $106.1 billion, up 7.3% year over year.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and $107.80 price target. CVS also declared a quarterly dividend of $0.665 per share, implying a 2.9% annual yield.

Western Financial Corp CA acquired a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 52,621 shares of the pharmacy operator's stock, valued at approximately $4,509,000. CVS Health comprises approximately 1.5% of Western Financial Corp CA's investment portfolio, making the stock its 17th biggest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kilter Group LLC purchased a new stake in shares of CVS Health in the second quarter valued at approximately $27,000. Sankala Group LLC purchased a new position in CVS Health during the fourth quarter worth approximately $28,000. Global Trust Asset Management LLC lifted its position in CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock worth $28,000 after buying an additional 300 shares in the last quarter. J.Safra Asset Management Corp acquired a new position in CVS Health during the second quarter worth $30,000. Finally, Beaird Harris Wealth Management LLC boosted its stake in CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator's stock worth $30,000 after buying an additional 195 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Strong Aetna Medicare Advantage quality ratings: More than 69% of Aetna’s Medicare Advantage members are enrolled in plans rated at least four stars for 2027. The result marks Aetna’s third consecutive year as one of the highest-performing large publicly traded Medicare Advantage providers and could support member retention, bonuses and the health-insurance segment’s turnaround. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: MinuteClinic accreditation renewed: MinuteClinic earned its seventh consecutive Joint Commission accreditation, with approximately 80% of surveyed locations offering primary care. Continued accreditation reinforces CVS’s positioning in retail and accessible outpatient healthcare services. MinuteClinic earns seventh consecutive Joint Commission accreditation
• Positive Sentiment: New pharmacy-focused location: CVS opened its first pharmacy-focused site in the Boston area, aimed at improving access to medications, immunizations and pharmacy care. The initiative could strengthen local prescription and clinical-service access, though its near-term financial impact is likely limited. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: Opioid case resolution provides certainty: CVS Pharmacy and related entities agreed to pay $315 million to resolve Justice Department allegations involving unlawful controlled-substance dispensing and false claims to federal programs. CVS admitted no wrongdoing and disputed the allegations; the settlement ends the case but includes enhanced prescription-monitoring obligations. CVS Agrees to Pay $315M for Illegally Filling Unlawful Opioid Prescriptions
• Negative Sentiment: Material legal and compliance cost: The $315 million payment reduces cash flow and profit while tighter DEA oversight could increase operating costs and constrain pharmacy prescription volumes. The allegations also renew concerns about historical controls and executive accountability, creating a negative overhang despite the case’s resolution. CVS to Pay $315 Million to Settle Opioid Allegations

CVS Health Trading Up 3.3%

Shares of CVS Health stock traded up $2.87 on Wednesday, reaching $90.42. The company had a trading volume of 9,331,173 shares, compared to its average volume of 8,352,747. The firm's 50 day moving average price is $91.88 and its two-hundred day moving average price is $92.87. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The firm has a market cap of $115.64 billion, a PE ratio of 23.92, a PEG ratio of 0.82 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. CVS Health's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the business posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be issued a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health's dividend payout ratio (DPR) is 70.37%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Wall Street Zen raised shares of CVS Health from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Leerink Partners cut their price objective on shares of CVS Health from $119.00 to $112.00 and set an "outperform" rating for the company in a research report on Monday. Wells Fargo & Company lifted their target price on shares of CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. Robert W. Baird set a $107.00 target price on shares of CVS Health in a report on Thursday, August 6th. Finally, Sanford C. Bernstein reissued an "outperform" rating and issued a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $107.80.

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.